L, G., CS, H., D, E., B, B., C, Z., M, T., . . . G, V. (2022). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
Citación estilo ChicagoL, Gianni, et al. Pathologic Complete Response (pCR) to Neoadjuvant Treatment With or Without Atezolizumab in Triple-negative, Early High-risk and Locally Advanced Breast Cancer: NeoTRIP Michelangelo Randomized Study. 2022.
Cita MLAL, Gianni, et al. Pathologic Complete Response (pCR) to Neoadjuvant Treatment With or Without Atezolizumab in Triple-negative, Early High-risk and Locally Advanced Breast Cancer: NeoTRIP Michelangelo Randomized Study. 2022.
Precaución: Estas citas no son 100% exactas.